Fig. 1.

Screen of the Cayman Epigenetics Screening Library. A549 cells in 96-well plates were pretreated with vehicle or compounds at a concentration of 0.25 μM (panel A) or 1 μM (panel B) for 2 h prior to infection with Ad-late/RFP (MOI 10). Cells were fixed at 24 hpi and RFP intensities were measured using the Cellomics ArrayScan VTI High Content Screening Platform. Changes in RFP levels were calculated as a percentage of vehicle treatment. Each data point represents the mean RFP percentage from three independent assays for one compound – error bars have been omitted for clarity. The RFP values for all 150 compounds were plotted in order of increasing magnitude (i.e. the compound numbers in the x-axis are arbitrary). While most compounds did not alter RFP expression from Ad-late/RFP, at both screen concentrations, several compounds were found to either significantly reduce or moderately enhance RFP levels.